The project on novel target-specific multiplexed nanophytomedicines for cancer therapy, funded by ICMR, focuses on the importance of dietary phytochemicals in sensitizing breast cancers that are resistant to chemodrugs such as Paclitaxel in clinical use.
The nanomedicine developed would be tested on appropriate animal models prior to which the material will be tested in vitro for its efficacy as well as toxicity effects.
